Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Cesano

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Neuro-Oncology|April 17, 2001
Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenograftsB Geoerger, C B Tang, A Cesano, et al.
Bone Marrow Transplantation|January 1, 1989
Lymphokine activated killer (LAK) activity in lymphoproliferative disordersR Foa, M T Fierro, D Raspadori, et al.
Blood|October 1, 1990
Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectorsR Foa, M T Fierro, D Raspadori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancerS Visonneau, A Cesano, D L Porter, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Neuro-Oncology|April 17, 2001
Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenograftsB Geoerger, C B Tang, A Cesano, et al.
Bone Marrow Transplantation|January 1, 1989
Lymphokine activated killer (LAK) activity in lymphoproliferative disordersR Foa, M T Fierro, D Raspadori, et al.
Blood|October 1, 1990
Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectorsR Foa, M T Fierro, D Raspadori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancerS Visonneau, A Cesano, D L Porter, et al.
Pageof 6